The Quantum-si products executive sells $5,570 worth of stock By Investing.com

The shares were traded at prices ranging from $1.23 to $1.37 per share, with an estimated average selling price of $1.2936 per share. Following this transaction, Vieceli retains ownership of 160,493 shares in the company. The sale was intended to cover withholding tax obligations related to the issuance of restricted stock units granted earlier in the year and was not a discretionary transaction by Vieceli. While the company maintains a strong earnings position with a current ratio of 13.4 and more cash than debt on its balance sheet, InvestingPro subscribers can access detailed insider trading patterns and 10+ additional exclusive insights about financial health and market conditions. While the company maintains a strong earnings position with a current ratio of 13.4 and more cash than debt on its balance sheet, InvestingPro subscribers can access detailed insider trading patterns and 10+ additional exclusive details about QSI’s financial health and market conditions.

The shares were traded at prices ranging from $1.23 to $1.37 per share, with an estimated average selling price of $1.2936 per share. Following this transaction, Vieceli retains ownership of 160,493 shares in the company. The sale was intended to cover withholding tax obligations related to the issuance of restricted stock units granted earlier in the year and was not a discretionary transaction by Vieceli.

In other recent news, Quantum-Si Incorporated has reported a major development. The company achieved a 232% revenue growth in the last year, marked by its innovative solutions in protein sequencing technology. Quantum-Si’s Q3 earnings fell short of expectations with a profit of about $787,000 due to delays in metal sales, but they produced a strong Q4 with revenue expected to surpass the $1 million mark.

The company also announced major layoffs and restructuring to streamline operations. In addition, Quantum-Si also achieved compliance with Nasdaq’s minimum bid price requirement, resolving a potential listing issue.

In terms of product development, Quantum-Si announced the first availability of its ProteoVue software, a tool designed to aid in proteomics research. The company also partnered with NVIDIA (NASDAQ: ) to develop its proteomics platform, Proteus™, using NVIDIA’s artificial intelligence and high-speed computing capabilities.

HC Wainwright maintained a buy rating on Quantum-Si and raised the price target to $5.50, following Quantum-Si’s recent investor day event. This is the latest news about Quantum-Si Incorporated.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.